Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2025
0mins
Should l Buy CVKD?
Source: Newsfilter
Economic Burden on LVAD Patients: Patients with left ventricular assist devices (LVAD) face significant medical and economic challenges, particularly due to high hospitalization costs associated with major bleeding events from oral anticoagulation, averaging $39,000 per event.
Potential of Tecarfarin: Cadrenal Therapeutics is developing tecarfarin, a novel oral anticoagulant that may provide a safer alternative to warfarin for LVAD patients, aiming to improve anticoagulation management by reducing drug interactions and complications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVKD
About CVKD
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics to overcome the limitations of anticoagulation therapy. It has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cadrenal Therapeutics Reports FY Losses
- Financial Performance: Cadrenal Therapeutics reported a FY GAAP EPS of -$6.64, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Cash Position: As of December 31, 2025, Cadrenal had cash and cash equivalents of $4 million, suggesting increased liquidity pressure on the company to maintain operations, potentially necessitating measures to ensure ongoing viability.
- Market Reaction: The reported losses have led to a cautious market outlook on Cadrenal's future prospects, likely resulting in stock price volatility and influencing investor decision-making.
- Investor Focus: Analysts and investors will closely monitor Cadrenal's subsequent financial performance and strategic responses to assess whether the company can reverse its current financial difficulties and achieve sustainable growth.
See More
Cadrenal Reports 2025 Financials and CAD-1005 Progress Update
- Clinical Trial Progress: On March 26, 2026, Cadrenal Therapeutics completed its End-of-Phase 2 meeting with the FDA for CAD-1005, clarifying the registrational path for its planned Phase 3 pivotal trial, marking a significant advancement in treating heparin-induced thrombocytopenia (HIT).
- Positive Clinical Results: In a randomized, blinded, placebo-controlled Phase 2 study of CAD-1005, the treatment group observed over a 25% reduction in thrombotic events, demonstrating CAD-1005's efficacy on top of standard anticoagulant therapy and providing crucial data for future clinical applications.
- Improved Financial Performance: Research and development expenses for Q4 2025 were $0.7 million, significantly down from $1.5 million in Q4 2024, while net loss decreased from $4.2 million to $3.0 million, indicating effective cost control and resource allocation by the company.
- Cash Flow Status: As of December 31, 2025, Cadrenal had $4.0 million in cash and cash equivalents, and the company is evaluating financing and strategic alternatives to support its clinical development activities, ensuring ongoing operations and project advancement.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
CAD-1005 Phase 2 Trial Shows Significant Reduction in Thrombotic Events
- Significant Efficacy: CAD-1005 demonstrated over a 25% absolute reduction in thrombotic events compared to placebo while showing no significant difference in platelet recovery rates, indicating its potential in treating thrombotic conditions.
- Clinical Trial Progress: The randomized, blinded, placebo-controlled trial concluded in December 2025 with a final dataset of 24 patients, supporting CAD-1005 as a first-line treatment for HIT, which could reshape current treatment paradigms.
- FDA Meeting Scheduled: Cadrenal has secured an End-of-Phase 2 meeting with the FDA to align on a Phase 3 registration path for CAD-1005, marking a significant milestone in its development and potentially accelerating its market entry.
- Broad Market Potential: As the only 12-LOX inhibitor in clinical development globally targeting the immune mechanisms of HIT, CAD-1005 addresses a critical unmet medical need, likely providing substantial market opportunities and competitive advantages for the company.
See More
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial
- Phase 2 Trial Progress: Cadrenal's anticoagulant drug VLX-1005 has completed its Phase 2 clinical trial, with data currently under analysis and expected to be published soon, indicating the company's potential in the anticoagulation sector despite a 4% drop in stock price prior to this announcement.
- FDA Fast Track Designation: VLX-1005 has received both Orphan Drug and Fast Track designations from the FDA, highlighting its potential market value in treating heparin-induced thrombocytopenia (HIT) and likely expediting subsequent regulatory approval processes.
- Market Demand Insight: Approximately 50,000 new HIT cases occur annually in the U.S., underscoring the urgent need for new therapies, with Cadrenal's product poised to fill gaps left by existing anticoagulants, particularly in the context of heparin use during cardiovascular surgeries.
- Other Development Programs: In addition to VLX-1005, Cadrenal is advancing Tecarfarin and Fruinexian, with the former targeting patients with end-stage kidney disease and the latter being a short-acting Factor XI inhibitor for cardiovascular surgery, demonstrating the company's diversified strategic approach in the anticoagulation field.
See More
Cadrenal Therapeutics Reports FY Losses
- Financial Performance: Cadrenal Therapeutics reported a FY GAAP EPS of -$6.64, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Cash Position: As of December 31, 2025, Cadrenal had cash and cash equivalents of $4 million, suggesting increased liquidity pressure on the company to maintain operations, potentially necessitating measures to ensure ongoing viability.
- Market Reaction: The reported losses have led to a cautious market outlook on Cadrenal's future prospects, likely resulting in stock price volatility and influencing investor decision-making.
- Investor Focus: Analysts and investors will closely monitor Cadrenal's subsequent financial performance and strategic responses to assess whether the company can reverse its current financial difficulties and achieve sustainable growth.
See More
Cadrenal Reports 2025 Financials and CAD-1005 Progress Update
- Clinical Trial Progress: On March 26, 2026, Cadrenal Therapeutics completed its End-of-Phase 2 meeting with the FDA for CAD-1005, clarifying the registrational path for its planned Phase 3 pivotal trial, marking a significant advancement in treating heparin-induced thrombocytopenia (HIT).
- Positive Clinical Results: In a randomized, blinded, placebo-controlled Phase 2 study of CAD-1005, the treatment group observed over a 25% reduction in thrombotic events, demonstrating CAD-1005's efficacy on top of standard anticoagulant therapy and providing crucial data for future clinical applications.
- Improved Financial Performance: Research and development expenses for Q4 2025 were $0.7 million, significantly down from $1.5 million in Q4 2024, while net loss decreased from $4.2 million to $3.0 million, indicating effective cost control and resource allocation by the company.
- Cash Flow Status: As of December 31, 2025, Cadrenal had $4.0 million in cash and cash equivalents, and the company is evaluating financing and strategic alternatives to support its clinical development activities, ensuring ongoing operations and project advancement.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
CAD-1005 Phase 2 Trial Shows Significant Reduction in Thrombotic Events
- Significant Efficacy: CAD-1005 demonstrated over a 25% absolute reduction in thrombotic events compared to placebo while showing no significant difference in platelet recovery rates, indicating its potential in treating thrombotic conditions.
- Clinical Trial Progress: The randomized, blinded, placebo-controlled trial concluded in December 2025 with a final dataset of 24 patients, supporting CAD-1005 as a first-line treatment for HIT, which could reshape current treatment paradigms.
- FDA Meeting Scheduled: Cadrenal has secured an End-of-Phase 2 meeting with the FDA to align on a Phase 3 registration path for CAD-1005, marking a significant milestone in its development and potentially accelerating its market entry.
- Broad Market Potential: As the only 12-LOX inhibitor in clinical development globally targeting the immune mechanisms of HIT, CAD-1005 addresses a critical unmet medical need, likely providing substantial market opportunities and competitive advantages for the company.
See More
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial
- Phase 2 Trial Progress: Cadrenal's anticoagulant drug VLX-1005 has completed its Phase 2 clinical trial, with data currently under analysis and expected to be published soon, indicating the company's potential in the anticoagulation sector despite a 4% drop in stock price prior to this announcement.
- FDA Fast Track Designation: VLX-1005 has received both Orphan Drug and Fast Track designations from the FDA, highlighting its potential market value in treating heparin-induced thrombocytopenia (HIT) and likely expediting subsequent regulatory approval processes.
- Market Demand Insight: Approximately 50,000 new HIT cases occur annually in the U.S., underscoring the urgent need for new therapies, with Cadrenal's product poised to fill gaps left by existing anticoagulants, particularly in the context of heparin use during cardiovascular surgeries.
- Other Development Programs: In addition to VLX-1005, Cadrenal is advancing Tecarfarin and Fruinexian, with the former targeting patients with end-stage kidney disease and the latter being a short-acting Factor XI inhibitor for cardiovascular surgery, demonstrating the company's diversified strategic approach in the anticoagulation field.
See More
